Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AfterNext HealthTech Acquisition Corp.AFTR · Entity 131185 | Director | August 11, 2021 | August 11, 2021 |
| MCKESSON CORPMCK · Entity 2904 | Director | July 22, 2026 | July 23, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP, Chief Patient Officer | February 24, 2022 | February 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AfterNext HealthTech Acquisition Corp.
Report date August 11, 2021 · Filed August 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class F Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-08-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share, which are convertible on a one-for-one basis into Class A Ordinary Shares, par value $0.0001 per share, automatically on the day of the closing of the Issuer's initial business combination. The Class F Ordinary Shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share, which are convertible on a one-for-one basis into Class A Ordinary Shares, par value $0.0001 per share, automatically on the day of the closing of the Issuer's initial business combination. The Class F Ordinary Shares have no expiration date.
MCKESSON CORP
Report date July 22, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 277 |
Reported balance
After 2026-07-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-22 · Grant · Acquired 277 · Balance 277 F1: RSUs granted pursuant to an annual grant under the 2022 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred until the Director leaves the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs granted pursuant to an annual grant under the 2022 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred until the Director leaves the Board.
Merck & Co., Inc.
Report date February 24, 2022 · Filed February 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,712.138 |
Reported balance
After 2022-02-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-02-24 · Grant · Acquired 9,550 · Balance 48,712.138 F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021. F2: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.
F2: Holdings include shares acquired in dividend reinvestment transactions.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CERNER Corp
Report date June 07, 2022 · Filed June 09, 2022
Section 16 reporting ended · disclosed 2022-06-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-06-07 transaction · row 1
1 source rowRow 1 · 2022-06-07 · Other · Disposed 15,032 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto) filed by Cedar Acquisition Corporation ("Merger Subsidiary") in connection with the Agreement and Plan of Merger, dated December 20, 2021 (as it may be amended or supplemented from time to time, the "Merger Agreement"), between Cerner Corporation ("Cerner") and Merger Subsidiary, which is a wholly owned subsidiary of OC Acquisition LLC ("Parent"), Parent, which is a wholly owned subsidiary of Oracle Corporation ("Oracle"), and Oracle. Pursuant to the Merger Agreement, on January 19, 2022, Oracle commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of Cerner common stock for a purchase price of $95.00 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. On June 7, 2022, Oracle accepted all shares tendered in the Offer. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto) filed by Cedar Acquisition Corporation ("Merger Subsidiary") in connection with the Agreement and Plan of Merger, dated December 20, 2021 (as it may be amended or supplemented from time to time, the "Merger Agreement"), between Cerner Corporation ("Cerner") and Merger Subsidiary, which is a wholly owned subsidiary of OC Acquisition LLC ("Parent"), Parent, which is a wholly owned subsidiary of Oracle Corporation ("Oracle"), and Oracle. Pursuant to the Merger Agreement, on January 19, 2022, Oracle commenced a cash tender offer (the "Offer") to acquire all of the issued and outstanding shares of Cerner common stock for a purchase price of $95.00 per share, net to the holders thereof in cash, without interest and subject to any required tax withholding. On June 7, 2022, Oracle accepted all shares tendered in the Offer.
HilleVax, Inc.
Report date September 17, 2025 · Filed September 17, 2025
Section 16 reporting ended · disclosed 2025-09-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-09-17 transaction · row 1
1 source rowRow 1 · 2025-09-17 · Other · Disposed 59,224 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2017 Filed Mar 6, 2017 17:26 UTC | CERNER Corp CERN · Entity 126375 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-018415 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · shares: These shares represent an award of restricted common stock that will vest on the following schedule: 1,500 shares on March 5, 2018; 1,500 shares on March 4, 2019; and 1,500 shares on March 3, 2020. F2 · balance_after: Includes 4,500 shares of restricted common stock. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,707 | $65.85 | $244,105.95 |
DisclosureSEC source: 0001225208-17-005086 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,062.79 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 16:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 38,647 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-16-041280 · doc4.xml · derivative · entry 7 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,647 shares Expires 2023-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 16:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 10,313 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-16-041280 · doc4.xml · derivative · entry 6 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,313 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 16:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 36,563 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-16-041280 · doc4.xml · derivative · entry 5 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,563 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 16:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 85,523 | $60.02 | $5,133,329.92 |
DisclosureSEC source: 0001225208-16-041280 · doc4.xml · nonDerivative · entry 4 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,115.242 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.1100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 16:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 10,313 | $36.56 | $377,043.28 |
DisclosureSEC source: 0001225208-16-041280 · doc4.xml · nonDerivative · entry 3 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,638.242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 16:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 36,563 | $39.29 | $1,436,560.27 |
DisclosureSEC source: 0001225208-16-041280 · doc4.xml · nonDerivative · entry 2 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,325.242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 16:51 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 38,647 | $44.98 | $1,738,342.06 |
DisclosureSEC source: 0001225208-16-041280 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,762.242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2016 Filed May 12, 2016 15:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 54,329 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-16-033206 · doc4.xml · derivative · entry 2 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,329 Underlying: Common Stock · 54,329 shares Expires 2026-05-09 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| May 06, 2016 Filed May 9, 2016 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,002 | $54.09 | $216,468.18 |
DisclosureSEC source: 0001225208-16-032904 · doc4.xml · derivative · entry 3 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,002 shares Expires 2016-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 06, 2016 Filed May 9, 2016 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,566 | $54.09 | $84,704.94 |
DisclosureSEC source: 0001225208-16-032904 · doc4.xml · nonDerivative · entry 2 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,654.646 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 06, 2016 Filed May 9, 2016 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-032904 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,220.646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2016 Filed Feb 24, 2016 17:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,377 | $50.77 | $171,450.29 |
DisclosureSEC source: 0001225208-16-027760 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,986.088 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 08, 2015 Filed May 11, 2015 17:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 19,208 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-15-011802 · doc4.xml · derivative · entry 5 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,208 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested and became exercisable in three equal installments beginning on 5/7/2011, 5/7/2012, and 5/7/2013. Read SEC document |
| May 08, 2015 Filed May 11, 2015 17:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-15-011802 · doc4.xml · derivative · entry 4 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,313 Underlying: Common Stock · 27,000 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable in three equal installments beginning on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| May 08, 2015 Filed May 11, 2015 17:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 38,368 | $60.99 | $2,339,949.22 |
DisclosureSEC source: 0001225208-15-011802 · doc4.xml · nonDerivative · entry 3 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,985.356 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.7400 to $61.1500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 08, 2015 Filed May 11, 2015 17:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 19,208 | $33.49 | $643,275.92 |
DisclosureSEC source: 0001225208-15-011802 · doc4.xml · nonDerivative · entry 2 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,353.356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2015 Filed May 11, 2015 17:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 27,000 | $36.56 | $987,120.00 |
DisclosureSEC source: 0001225208-15-011802 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,145.356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 3,818 | $59.86 | $228,545.48 |
DisclosureSEC source: 0001225208-15-011274 · doc4.xml · derivative · entry 4 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,818 shares Expires 2015-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,214 | $59.86 | $72,670.04 |
DisclosureSEC source: 0001225208-15-011274 · doc4.xml · nonDerivative · entry 2 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,145.356 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-011274 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,359.356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 49,536 | $0.00 Strike: $59.86 | $0.00 |
DisclosureSEC source: 0001225208-15-011274 · doc4.xml · derivative · entry 3 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,536 Underlying: Common Stock · 49,536 shares Expires 2025-04-30 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 16:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 2,736 | $58.30 | $159,508.80 |
DisclosureSEC source: 0001225208-15-005604 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,374.436 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/30/2012. Performance shares were paid out at 102 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.